Home › Major Depressive Disorder › Arkansas
Major Depressive Disorder clinical trials in Arkansas
13 studies for Major Depressive Disorder are looking for participants at sites in Arkansas.
Cities in Arkansas
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- Preferred Research Partners, Inc., Little Rock
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Nov 9, 2026 · NCT07592689Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- SanRo Clinical Research Group LLC WCG Clinical Network, Bryant
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Nov 3, 2026 · NCT06559306A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- SanRo Clinical Research Group LLC WCG Clinical Network, Bryant
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Nov 3, 2026 · NCT07573176Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Bryant
- Neurocrine Clinical Site, Little Rock
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT06966401Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
- Woodland Research Northwest (ERG), Rogers
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Oct 28, 2026 · NCT07226661Study of ALTO-300 in MDD
- Site 193, Rogers
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Oct 26, 2026 · NCT05922878A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
- Draig Clinical Site, Little Rock
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Oct 14, 2026 · NCT07610473A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
- Draig Clinical Site, Bentonville
- Draig Clinical Site, Little Rock
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Oct 8, 2026 · NCT07300969Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
- Vanda Investigational Site, Little Rock
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 24, 2026 · NCT06830044A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Bryant
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07105111NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Bryant
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT06911112A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
- Preferred Research Partners /ID# 279206, Little Rock
- Woodland International Research Group /ID# 277605, Little Rock
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Jun 15, 2026 · NCT07276997Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Little Rock
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 29, 2025 · NCT06786624From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.